Clinical Trial: A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application

Brief Summary: The purpose of this study is to evaluate the safety of the designed LMP1－CAR －T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.

Detailed Summary: Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.
Sponsor: The Second Hospital of Nanjing Medical University

Current Primary Outcome: all cause mortality [ Time Frame: one year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: The Second Hospital of Nanjing Medical University

Dates:
Date Received: November 30, 2016
Date Started: November 2016
Date Completion: December 2017
Last Updated: November 30, 2016
Last Verified: November 2016